ReviewJournal of pediatric intensive care2022
Clinicolaboratory Profile, Treatment, Intensive Care Needs, and Outcome of Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2: A Systematic Review and Meta-analysis.
Review in Journal of pediatric intensive care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- In-hospital unfavorable outcomes of MIS-C during 2020-2022: a systematic review.European journal of pediatrics · 2024Pooled it
- Evidence linking COVID-19 and the health/well-being of children and adolescents: an umbrella review.BMC medicine · 2024Pooled it
- Cardiac Injury in COVID-19: A Systematic Review of Relevant Meta-Analyses.Reviews in cardiovascular medicine · 2022Pooled it
- Neurological and Neuropsychiatric Manifestations of Pediatric Inflammatory Multisystem Syndrome (PIMS/MIS-C): A Narrative Review.Journal of personalized medicine · 2026Review
- Research Progress on Coronary Artery Injury and Myocardial Ischemia in Multisystem Inflammatory Syndrome in Children.Current issues in molecular biology · 2026Review
- MIS-C: Diagnosis, Management, and Outcomes.Open forum infectious diseases · 2026Review
- Development and Validation of Multivariable Machine-Learning Models for the Prediction of Multisystemic Inflammatory Syndrome Outcomes in Latin American Children.Acta paediatrica (Oslo, Norway : 1992) · 2026Observational
- Echocardiographic findings of hospitalized children with covid-19: A cross-sectional study in southeast Iran.ARYA atherosclerosis · 2025Article
- The evaluation of the burden of multisystem inflammatory syndrome in children on health economics.Archives of rheumatology · 2024Article
- Description and outcomes of Afro-Caribbean children treated for multisystem inflammatory syndrome in the French West Indies.Heliyon · 2023Article
- COVID-19 and Laboratory Markers from Romanian Patients-A Narrative Review.Life (Basel, Switzerland) · 2023Review
- Comparison of Multisystem Inflammatory Syndrome (MIS-C) and Dengue in Hospitalized Children.Indian journal of pediatrics · 2023Article
- Respiratory Care in Children with COVID-19.Journal of pediatric intensive care · 2023Review
- Nutraceuticals for Complementary Treatment of Multisystem Inflammatory Syndrome in Children: A Perspective from Their Use in COVID-19.Life (Basel, Switzerland) · 2022Review
- Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2.Indian journal of pediatrics · 2022Article
- Evaluation of Baseline Characteristics and Prognostic Factors in Multisystemic Inflammatory Syndrome in Children: Is It Possible to Foresee the Prognosis in the First Step?Journal of clinical medicine · 2022Article
- Pathogenic Connections in Post-COVID Conditions: What Do We Know in the Large Unknown? A Narrative Review.Viruses · 2022Review
- Clinical practice guidelines in multisystem inflammatory syndrome (MIS-C) related to COVID-19: a critical review and recommendations.World journal of pediatrics : WJP · 2022Review
- Hemorrhagic Nonpurulent Conjunctivitis in MIS-C.Indian journal of pediatrics · 2022Article
- Best Practice Recommendations for the Diagnosis and Management of Children With Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 (PIMS-TS; Multisystem Inflammatory Syndrome in Children, MIS-C) in Switzerland.Frontiers in pediatrics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was aimed to summarize the current data on clinicolaboratory features, treatment, intensive care needs, and outcome of pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2; PIMS-TS) or multisystem inflammatory syndrome in children (MIS-C). Articles published in PubMed, Web of Science, Scopus, Google Scholar, and novel coronavirus disease 2019 (COVID-19) research database of World Health Organization (WHO), Centers for Disease Control and Prevention (CDC) database, and Cochrane COVID-19 study register between December 1, 2019 and July 10, 2020. Observational studies involving patients <21 years with PIMS-TS or MIS-C were reported the clinicolaboratory features, treatment, intensive care needs, and outcome. The search identified 422 citations and finally 18 studies with 833 participants that were included in this study, and pooled estimate was calculated for parameters of interest utilizing random effect model. The median age was 9 (range: 8-11) years. Fever, gastrointestinal symptoms, rash, conjunctival injection, and respiratory symptoms were common clinical features. Majority (84%) had positive SARS-CoV-2 antibody test and only one-third had positive reverse transcript polymerase chain reaction (RT-PCR). The most common laboratory abnormalities noted were elevated C-reactive protein (CRP), D-dimer, procalcitonin, brain natriuretic peptide (BNP), fibrinogen, ferritin, troponin, interleukin 6 (IL-6), lymphopenia, hypoalbuminemia, and thrombocytopenia. Cardiovascular complications included shock (65%), myocardial dysfunction (61%), myocarditis (65%), and coronary artery abnormalities (39%). Three-fourths of children required admission to pediatric intensive care unit (PICU) where they received vasoactive medications (61%) and mechanical ventilation (25%). Treatment strategies used included intravenous immunoglobulin (IVIg; 82%), steroids (54%), antiplatelet drugs (64%), and anticoagulation (51%). Mortality for patients with PIMS-TS or MIS-C was low (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.